+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Crohn's Disease Therapeutics Market by Therapeutics Class, Route Of Administration, Distribution Channel, Age Group - Global Forecast 2025-2030- Product Image
Crohn's Disease Therapeutics Market by Therapeutics Class, Route Of Administration, Distribution Channel, Age Group - Global Forecast 2025-2030- Product Image
Sale

Crohn's Disease Therapeutics Market by Therapeutics Class, Route Of Administration, Distribution Channel, Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6014389
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Crohn's Disease Therapeutics Market grew from USD 12.76 billion in 2023 to USD 13.36 billion in 2024. It is expected to continue growing at a CAGR of 5.47%, reaching USD 18.54 billion by 2030.

The Crohn's Disease Therapeutics market encompasses a wide array of pharmaceutical drugs and biologics designed to manage the inflammatory symptoms associated with Crohn's disease, a chronic inflammatory bowel disease. This market is driven by the necessity to provide effective treatments that enhance patient quality of life amidst the growing prevalence of Crohn's disease worldwide. Applications extend across several therapeutic areas, including biologic therapies, immunomodulators, corticosteroids, and others, highlighting end-user segments such as hospitals, specialty clinics, and research institutes. Key growth factors influencing this market include increasing incidence rates, advancements in biologics and targeted therapies, and a heightened focus on personalized medicine. Furthermore, ongoing research aiming to uncover genetic factors tied to Crohn's disease presents significant opportunities for innovative drug development and personalized treatment plans. Nonetheless, stringent regulatory frameworks, high drug development costs, and potential side effects of long-term drug use pose substantial challenges. Competitive pressure from biosimilars as patents expire further complicates market dynamics. However, with governments and healthcare organizations investing in R&D, there’s a fertile ground for innovation in oral therapies and non-invasive administration routes. Additionally, advancements in microbiome-based therapeutics, aiming to modulate gut health, represent an untapped avenue for exploration. Collaborations between biotech firms and research institutions can spur innovation and expedite clinical trials. The nature of the Crohn's Disease Therapeutics market is rapidly evolving, marked by an increasing shift towards biologics and precision medicine. Vendors can optimize growth by leveraging data analytics to refine patient stratification, thus personalizing therapeutic approaches. Recommendations include investing in advanced biotechnology R&D, fostering partnerships across the healthcare ecosystem, and streamlining manufacturing processes to reduce costs. Navigating market constraints requires strategic diligence, continuous innovation, and actionable insights to capture emerging opportunities effectively, ensuring long-term business efficiency and market leadership.

Understanding Market Dynamics in the Crohn's Disease Therapeutics Market

The Crohn's Disease Therapeutics Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Growing demand for targeted Crohn’s disease treatments due to better patient outcomes
    • Expanded healthcare infrastructure and accessibility in developing regions for Crohn’s disease treatment
    • Government initiatives and funding to support Crohn’s disease research and new drug development
    • Collaborations between biotech firms and research institutions for novel Crohn’s disease therapeutics
  • Market Restraints
    • Stringent regulatory requirements slow down the approval of new Crohn's disease treatments
    • Lack of robust clinical trial data diminishes confidence in Crohn's disease therapeutics
  • Market Opportunities
    • Developing sustainable and cost-effective biologic therapies for long-term management of Crohn's disease
    • Exploring the potential of gut microbiome modulation therapies in the treatment of Crohn's disease
    • Expanding the use of precision medicine in identifying individual patient response to Crohn's disease treatments
  • Market Challenges
    • Addressing patient adherence and long-term commitment to Crohn's disease therapeutic regimens
    • Managing high costs and insurance barriers associated with advanced Crohn's disease treatments

Exploring Porter’s Five Forces for the Crohn's Disease Therapeutics Market

Porter’s Five Forces framework further strengthens the insights of the Crohn's Disease Therapeutics Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Crohn's Disease Therapeutics Market

External macro-environmental factors deeply influence the performance of the Crohn's Disease Therapeutics Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Crohn's Disease Therapeutics Market

The Crohn's Disease Therapeutics Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Crohn's Disease Therapeutics Market

The Crohn's Disease Therapeutics Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Crohn's Disease Therapeutics Market

The Crohn's Disease Therapeutics Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Crohn's Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Ferring Pharmaceuticals Inc., Gilead Sciences Inc., Ipsen Biopharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Nestlé Health Science, Novartis AG, Pfizer Inc., Roche Holding AG, Sanofi S.A., Shire plc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and UCB S.A..

Market Segmentation & Coverage

This research report categorizes the Crohn's Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Therapeutics Class
    • Biologics
      • Anti-Integrin Therapy
      • Interleukin Inhibitors
      • Monoclonal Antibodies
    • Conventional Drugs
      • Aminosalicylates
      • Corticosteroids
      • Immunosuppressants
  • Route Of Administration
    • Oral
      • Capsules
      • Tablets
    • Parenteral
      • Injectables
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • Age Group
    • Adults
    • Pediatric
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing demand for targeted Crohn’s disease treatments due to better patient outcomes
5.1.1.2. Expanded healthcare infrastructure and accessibility in developing regions for Crohn’s disease treatment
5.1.1.3. Government initiatives and funding to support Crohn’s disease research and new drug development
5.1.1.4. Collaborations between biotech firms and research institutions for novel Crohn’s disease therapeutics
5.1.2. Restraints
5.1.2.1. Stringent regulatory requirements slow down the approval of new Crohn's disease treatments
5.1.2.2. Lack of robust clinical trial data diminishes confidence in Crohn's disease therapeutics
5.1.3. Opportunities
5.1.3.1. Developing sustainable and cost-effective biologic therapies for long-term management of Crohn's disease
5.1.3.2. Exploring the potential of gut microbiome modulation therapies in the treatment of Crohn's disease
5.1.3.3. Expanding the use of precision medicine in identifying individual patient response to Crohn's disease treatments
5.1.4. Challenges
5.1.4.1. Addressing patient adherence and long-term commitment to Crohn's disease therapeutic regimens
5.1.4.2. Managing high costs and insurance barriers associated with advanced Crohn's disease treatments
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Crohn's Disease Therapeutics Market, by Therapeutics Class
6.1. Introduction
6.2. Biologics
6.2.1. Anti-Integrin Therapy
6.2.2. Interleukin Inhibitors
6.2.3. Monoclonal Antibodies
6.3. Conventional Drugs
6.3.1. Aminosalicylates
6.3.2. Corticosteroids
6.3.3. Immunosuppressants
7. Crohn's Disease Therapeutics Market, by Route Of Administration
7.1. Introduction
7.2. Oral
7.2.1. Capsules
7.2.2. Tablets
7.3. Parenteral
7.3.1. Injectables
8. Crohn's Disease Therapeutics Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacies
8.3. Online Pharmacies
8.4. Retail Pharmacies
9. Crohn's Disease Therapeutics Market, by Age Group
9.1. Introduction
9.2. Adults
9.3. Pediatric
10. Americas Crohn's Disease Therapeutics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Crohn's Disease Therapeutics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Crohn's Disease Therapeutics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. CROHN'S DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
FIGURE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 17. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. CROHN'S DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 23. CROHN'S DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CROHN'S DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CROHN'S DISEASE THERAPEUTICS MARKET DYNAMICS
TABLE 7. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ANTI-INTEGRIN THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INTERLEUKIN INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AMINOSALICYLATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 45. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 46. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 58. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 59. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 60. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 61. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 63. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 64. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 65. CANADA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 66. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 67. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 68. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 69. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 70. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 71. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 72. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 73. MEXICO CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. ASIA-PACIFIC CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 98. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 99. AUSTRALIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 100. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 101. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 102. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 103. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 105. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 106. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 107. CHINA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 108. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 109. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 110. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 111. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 113. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 114. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 115. INDIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 116. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 117. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 118. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 119. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 120. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 121. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 122. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 123. INDONESIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 125. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 126. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 127. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 128. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 129. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 130. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. JAPAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 132. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 133. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 134. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 135. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 137. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 138. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. MALAYSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 141. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 142. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 143. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 145. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 146. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 147. PHILIPPINES CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 148. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 149. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 150. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 151. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 152. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 153. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 154. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 155. SINGAPORE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 156. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 157. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 158. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 159. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 160. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 161. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 162. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 163. SOUTH KOREA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 164. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 165. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 166. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 167. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 169. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 170. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 171. TAIWAN CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 172. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 173. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 174. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 175. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 176. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 177. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 178. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 179. THAILAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 180. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 181. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 182. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 183. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 184. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 185. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 186. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. VIETNAM CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 190. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 191. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 192. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 193. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 194. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. EUROPE, MIDDLE EAST & AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 197. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 198. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 199. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 200. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 201. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 202. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 203. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. DENMARK CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 206. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 207. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 208. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 210. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 211. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 212. EGYPT CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 214. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 215. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 216. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 217. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 218. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 219. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 220. FINLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 221. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 222. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 223. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 224. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 226. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 227. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. FRANCE CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 229. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 230. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 231. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 232. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 234. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 235. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. GERMANY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 245. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 246. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 247. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 248. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 249. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 250. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 251. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. ITALY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 254. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 255. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 256. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 258. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 259. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. NETHERLANDS CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 261. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 262. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 263. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 264. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 265. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 266. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 267. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 268. NIGERIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 269. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 270. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 271. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 272. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 273. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 274. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 275. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. NORWAY CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 277. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 278. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 279. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 280. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 282. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 283. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 284. POLAND CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 285. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 286. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 287. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 288. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 289. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 290. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 291. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 292. QATAR CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 293. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 294. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 295. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 296. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 297. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 298. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 299. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 300. RUSSIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 301. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 302. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 303. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 304. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 305. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 306. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2030 (USD MILLION)
TABLE 307. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 308. SAUDI ARABIA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 309. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 310. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 311. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DRUGS, 2018-2030 (USD MILLION)
TABLE 312. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 313. SOUTH AFRICA CROHN'S DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 314.

Companies Mentioned

The leading players in the Crohn's Disease Therapeutics Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Ferring Pharmaceuticals Inc.
  • Gilead Sciences Inc.
  • Ipsen Biopharmaceuticals, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Nestlé Health Science
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi S.A.
  • Shire plc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 13.36 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.54 Billion
Compound Annual Growth Rate5.4%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Crohn's Disease Therapeutics Market Size, Share & Trends Analysis Report By Type, By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Crohn's Disease Therapeutics Market Size, Share & Trends Analysis Report By Type, By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacies), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Crohn's Disease Therapeutics Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Distribution Channel, and Geography - Product Image

Crohn's Disease Therapeutics Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Distribution Channel, and Geography

  • Report
  • 150 Pages
  • Global
From
Crohn's Disease - Pipeline Insight, 2024 - Product Image

Crohn's Disease - Pipeline Insight, 2024

  • Clinical Trials
  • 240 Pages
  • Global
From
Crohns Disease - Pipeline Insight, 2024 - Product Image

Crohns Disease - Pipeline Insight, 2024

  • Drug Pipelines
  • 100 Pages
  • Global
From
Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 120 Pages
  • Global
From

About the Crohn Disease Drug Market

Crohn Disease is a chronic inflammatory disorder of the gastrointestinal tract, and is one of the most common immune disorders. Treatment for Crohn Disease typically involves a combination of medications, lifestyle changes, and in some cases, surgery. Common medications used to treat Crohn Disease include corticosteroids, immunomodulators, biologic therapies, and antibiotics. Corticosteroids are used to reduce inflammation, while immunomodulators are used to suppress the immune system. Biologic therapies are used to target specific proteins in the body that are involved in the inflammatory process, and antibiotics are used to treat bacterial infections. The Crohn Disease Drug market is a rapidly growing segment of the Immune Disorders Drugs market. It is driven by the increasing prevalence of Crohn Disease, as well as the development of new and innovative treatments. Companies in the market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Pfizer, and UCB. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.